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ABSTRACT
Purpose. This nationwide study evaluated results of cy-
toreductive surgery (CRS) combined with hyperthermic
intraperitoneal chemotherapy (HIPEC) for peritoneal
metastasis of colorectal origin in the Netherlands following
a national protocol.
Methods. In a multi-institutional study prospective dat-
abases of patients with peritoneal carcinomatosis (PC)
from colorectal cancer and pseudomyxoma peritonei
(PMP) treated according to the Dutch HIPEC protocol, a
uniform approach for the CRS and HIPEC treatment, were
reviewed. Primary end point was overall survival and
secondary end points were surgical outcome and progres-
sion-free survival.
Results. Nine-hundred sixty patients were included; 660
patients (69 %) were affected by PC of colorectal carci-
noma and the remaining suffered from PMP (31 %). In 767
procedures (80 %), macroscopic complete cytoreduction
was achieved. Three-hundred and thirty one patients had
grade III–V complications (34 %). Thirty-two patients died
perioperatively (3 %). Median length of hospital stay was
16 days (range 0–166 days). Median follow-up period was
41 months (95 % confidence interval (CI), 36–46 months).
Median progression-free survival was 15 months (95 % CI
13–17 months) for CRC patients and 53 months (95 % CI
40–66 months) for PMP patients. Overall median survival
was 33 (95 % CI 28–38 months) months for CRC patients
and 130 months (95 % CI 98–162 months) for PMP
patients. Three- and five-year survival rates were 46 and
31 % respectively in case of CRC patients and 77 and
65 % respectively in case of PMP patients.
Conclusions. The results underline the safety and efficacy
of cytoreduction and HIPEC for PC from CRC and PMP. It
is assumed the uniform Dutch HIPEC protocol was
beneficial.
Cytoreductive surgery (CRS) and hyperthermic intra-
peritoneal chemotherapy (HIPEC) as a treatment for
peritoneal surface malignancies remains the subject to
debate, especially amongst nonexperts. It was questioned
whether there is enough scientific evidence for this high-
risk procedure (New York Times, August 11, 2011). In the
Netherlands, the outcome of this treatment was evaluated
by a randomized, controlled trial published in 2003, which
showed survival benefit for patients treated with CRS–
HIPEC compared to chemotherapy and palliative surgery
in an intention to treat analysis.1 Results of this trial were
obtained in a single-expert centre. Because the benefits of
the treatment were established, CRS–HIPEC procedures
became widely available in now six hospitals in the
Netherlands.
During the past decades, the incidence of colorectal
carcinoma (CRC) has increased worldwide. Colorectal
carcinoma is the second most common cancer in the
Netherlands with an incidence of 12,000 new cases per
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year. In 2010, the colorectal mortality was 12 % of all
cancer death in the Netherlands, with most deaths due to
metastatic disease.2 Besides liver metastases, peritoneal
metastases are a common sign of tumour progression or
recurrence of colorectal cancer. Two population-based
studies reported recently incidences of synchronous peri-
toneal metastasis of 4.3 and 4.8 %. Metachronous
metastasis was reported to a rate of 4.2 %.3,4
Peritoneal metastases are generally associated with a poor
prognosis. In a multicentre, prospective study, published in
the year 2000, median overall survival was 5.2 months for
patients with colorectal cancer, and all patients with this
condition had a fatal outcome.5 Few studies have been
performed to study the effect of chemotherapy on peritoneal
metastasis of colorectal cancer. A median survival of
6 months was reported of patients with PC primarily treated
with 5-FU and leucovorin.6 For patients with PC as the only
metastatic site treated with systemic chemotherapy and
palliative surgery somewhat better results were reported
with a median overall survival of 12.6 months.1,7 In recently
published subanalyses of chemotherapy studies, patients
with peritoneal carcinomatosis had a poorer prognosis than
patients with other metastatic sites, independent of the
chemotherapy regimen.8,9
Because systemic chemotherapy has not been very efficient
to treat intra-abdominal tumor dissemination, novel therapies
were developed.10 CRS–HIPEC is now becoming the pre-
ferred treatment option for many peritoneal surface
malignancies, such as peritoneal metastasis of colorectal can-
cer, malignant peritoneal mesothelioma, and pseudomyxoma
peritonei (PMP).11 This treatment consists of local disease
control by macroscopic complete cytoreductive surgery
combined with hyperthermic intraperitoneal chemotherapy to
remove microscopic residual disease completely.
The CRS–HIPEC treatment can improve survival of
patients with peritoneal metastasis of colorectal cancer.
Five-year survival rates of between 19 and 51 % have been
reported.12–14 For PMP patients, 5-year survival rates of
73–86 % have been reported.14,15 Throughout the world,
the CRS–HIPEC procedure is adopted as a possible cura-
tive procedure for peritoneal surface malignancies.
However, there are many different treatment regimens for
cytoreduction and HIPEC. The timing of the intraperitoneal
chemotherapy is not universal. Possible treatment sched-
ules include intraoperative intraperitoneal chemotherapy,
early postoperative intraperitoneal chemotherapy (EPIC),
or both. Also, several different chemotherapeutic drugs are
used and applied in different doses and regimens.15,16
The question remains whether CRS–HIPEC once per-
formed on a wider scale is beneficial. In this study, we
analysed the results of all CRS and HIPEC treatments in




All patients that underwent CRS–HIPEC for peritoneal
disease from colorectal origin in the Netherlands were
included. The peritoneal malignancies originated from
colorectal cancer, appendiceal cancer, or pseudomyxoma
peritonei (PMP). Patients were included between Novem-
ber 1995 and June 2012. The different institutions started at
different time points (Fig. 1).
Treatment
The institutions performed the CRS–HIPEC procedure
under the same standardized protocol. Extensive debulking
with peritonectomy and, when needed, multiorgan resec-
tions were performed, as described by Sugarbaker et al.10,11
and all the latter recommendations. The purpose of the cy-
toreduction was to obtain a macroscopically complete CRS
(R1) resection, which means that no macroscopically visible
residual tumor was left at the end of the surgical resection.
After the cytoreduction, the open perfusion protocol of the
abdominal cavity with mitomycin C was performed.17 The
inflow temperature of the perfusate was 41–42 C. As soon
as this temperature was reached, mitomycin C was added,
35 mg/m2 body surface, in three fractions (one half, one
fourth, and one fourth of the total dose) with a 30-min
interval. Mitomycin C was used under the same schedule for
all first HIPEC procedures. If a patient had undergone a
HIPEC before, procedures were done with intraperitoneal
oxaliplatin (460 mg/m2), systemic folinic acid (20 mg/m2),
and 5-fluorouracil (5-FU; 400 mg/m2). When new institu-
tions started performing CRS–HIPEC, a surgeon of an
experienced institute monitored the procedure to ensure that
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FIG. 1 Cumulative number of patients who underwent CRS-HIPEC
in the Netherlands over the years
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Data Collection and Analysis
Prospective databases and medical charts were reviewed
for patient’s characteristics, operative details, pathology
reports, and outcome. In colorectal carcinoma, histological
mucinous adenocarcinoma was defined as carcinoma with
50 % of mucus. If there were any signet ring cells found in
the tumour, it was considered a signet ring cell carcinoma.
The participating hospitals used different classification
methods for PMP. The classification system first described
by Ronnett et al.18 that classifies PMP in DPAM, PMCA,
and PMCA-I was used. Also, the more recent classification
in low (DPAM) and high (PMCA/I) grade PMP was used,
presented by the WHO in 2010.19 For this study, the latter
grading system was applied or converted into. Tumour load
was measured by counting the affected abdominal regions
(0–7).20
Completeness of CRS was determined according to the
maximum thickness of tumor nodules left behind. No
residual macroscopic tumor was graded as an R1 resection,
residual macroscopic tumor \2.5 mm was recorded as an
R2a resection and if more disease was left behind, this was
graded as an R2b resection.13 Hospital stay was defined as
time in days from date of surgery to discharge. Morbidity
was graded by the National Cancer Institute’s Common
Toxicity Criteria of Adverse Events version 4.0 (CTCAE
v4.0).21 For every procedure, the complication with the
highest grade was listed.
Survival was analysed separately for colorectal cancer
and PMP patients because of the different course of the
disease. Progression-free survival was measured from the
date of the HIPEC procedure until date of progression of
the disease or date of last follow-up in censored cases.
Overall survival was measured by the date of the HIPEC
procedure and date of death or last follow-up date. Median
progression free and overall survivals were expressed in
months. Furthermore, 3- and 5-year overall survival rates
were measured.
Statistical Analysis
Clinicopathological characteristics and surgical outcome
were analyzed by descriptive statistics. Categorical vari-
ables were compared using Chi-square analysis or Fisher’s
exact test where appropriate. Normally distributed variables
were compared using the t test or one-way ANOVA as
appropriate, nonparametric tests were used when variables
were not normally distributed. Survival was measured with
the Kaplan–Meier method. p \ 0.05 was considered sig-
nificant in all analysis. Survival analysis was performed
under intention-to-treat conditions, which means that
patients with incomplete resections were included. All
statistical analyses were conducted using SPSS software
(version 20, SPSS Inc., Chicago, IL, USA).
RESULTS
Clinicopathological characteristics are presented in
Table 1; 960 patients were included in the study, and 660
patients were affected by PC of colorectal cancer (69 %)
and the remaining suffered from PMP (31 %). Median age
at the time of the CRS and HIPEC procedure was 58 years
for both CRC (range 21–79 years) and PMP (range
28–81 years; p = 0.271); 386 patients (40 %) were male.
the Netherlands Cancer Institute included 554 patients until
2012, St. Antonius Hospital Nieuwegein 151 patients,
University Medical Centre Groningen 72 patients, Catha-
rina Hospital Eindhoven 151 patients, Radboud University
Nijmegen Medical Center 13 patients, and VU medical
centre 19 patients. The total number of CRS and HIPEC
procedures per year increased from 21 in 1995 to 136
procedures in 2011. The cumulative number of patients
included in this study over time is shown in Fig. 1.
The primary tumour of the colorectal cancer patients
was located in the appendix (9 %), right colon (29 %),
transverse colon (5 %), left colon (8 %), and rectosigmoid
(47 %). Most of the patients had intestinal-type adenocar-
cinoma (84 %); a lower number of patients had mucinous
adenocarcinoma (12 %) or signet ring cell carcinoma
(4 %). Tumour differentiation was mentioned in the
pathology report in 56 % of the cases. Six percent of
tumours were well differentiated, 37 % were moderately
differentiated, and 13 % were poorly differentiated. Lymph
nodes were involved at the time of the primary resection in
55 % of the patients. Synchronous peritoneal metastases
were found in 45 % of the patients.
Patients with PMP had a primary neoplasm in the
appendix in 86 % of the cases. The other 14 % were found
in the caecal region, elsewhere in the colon, or in the
ovaries. In little cases, no primary lesion was found. Not all
pathology reports (37 %) mentioned subclassification of
PMP. Forty-seven percent of the patients had low-grade
PMP and 16 % had high-grade PMP. Median abdominal
regions affected were 3 (range 1–7) regions for the CRC
patients and 5 (range 1–7) regions for the PMP patients
(p \ 0.001).
Surgical outcome and morbidity are presented in
Table 2. In 767 patients (80 %), an R1 cytoreduction was
achieved. Major complications, grade III–V, occurred in
331 (34 %) procedures. Thirty-two patients died from a
complicated procedure; consequently the mortality rate
was 3 %. The most common cause of mortality was
anastomotic leakage. Median hospital stay was 16 days
(95 % confidence interval (CI) 13–22 days).
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TABLE 1 Clinicopathological
characteristics
CRC colorectal carcinoma, PMP
pseudomyxoma peritonei
1 Netherlands Cancer Institute—
Antoni van Leeuwenhoek,
Amsterdam, 2 Antonius Hospital
Nieuwegein, 3 University Medical
Centre Groningen, 4 Catharina
Hospital Eindhoven, 5 Radboud
University Nijmegen Medical
Center, 6 VU medical centre,
Amsterdam
a Patients were included to 2012
where the data were available
b Mann–Whitney U test
c Chi-square test
CRC PMP p value
Characteristic No. of patients No. of patients
n = 660 n = 300
Age (year)
Median (range) 58 (21–79) 58 (28–81) 0.271b
Gender
Male 297 45 % 89 30 % \0.001c
Female 363 55 % 210 70 %
Hospital
1 334 51 % 220 73 %
2 121 18 % 30 10 %
3 48 7 % 24 8 %
4 128 19 % 23 8 %
5 12 2 % 1 0.3 %
6 17 3 % 2 0.7 %
Year of surgery
1995–1999 61 12/year 44 9/year
2000–2004 89 18/year 69 14/year
2005–2009 274 55/year 116 23/year
2010 101 101/year 27 27/year
2011 102 102/year 34 34/year
2012a 33 10
Primary localisation
Appendix 62 9 %
Right colon 193 29 %
Transverse colon 30 5 %
Left colon 51 8 %
Rectosigmoid 308 47 %
Unknown 16 2 % 43 14 %
Histology 24 4 %
Intestinal type
Signet cell ring 556 84 %
Mucinous 24 4 %
Low grade 70 13 % 140 47 %
High grade 49 16 %
Unknown 111 37 %
Tumour differentiation
Well 36 6 %
Moderately 203 37 %
Poor 70 13 %
Unknown 247 44 %
Lymph node involvement
Positive 365 55 %
Negative 192 29 %
Unknown 103 16 %
Synchronous PC
Yes 299 45 %
No 269 41 %
Unknown 92 14 %
Abdominal region involvement
Median (range) 3 (1–7) 5 (1–7) \0.001b
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Survival was analysed separately for peritoneal metas-
tasis of colorectal carcinoma and PMP (Table 3); 401
patients were deceased (42 %) at the time of analysis.
Median follow-up time was 41 months (95 % CI
36–46 months). Median progression-free survival (PFS)
for colorectal carcinoma patients was 15 months (95 % CI
13–17 months; Fig. 2a). For PMP patients, median pro-
gression-free survival was 53 months (95 % CI
40–60 months; Fig. 2b). Median overall survival (OS) for
colorectal carcinoma patients was 33 months (95 % CI
28–38 months). The 3-year survival rate was 46 %, and the
5-year survival rate was 31 % (Fig. 2a). For PMP patients
the median OS was 130 months (95 % CI 98–162 months).
The 3-year survival rate for PMP patients was 77 % and
the 5-year survival rate was 65 % (Fig. 2b).
DISCUSSION
Since the first publication of Sugarbaker on CRS–HI-
PEC as a possible curative treatment for peritoneal surface
malignancies, many institutions started to perform this
procedure.10 All centres in the Netherlands agreed on
monitoring safety of the CRS and HIPEC and adopted the
uniform Dutch HIPEC protocol. The combined results of
all centres showed a median survival of 33 months (95 %
CI 28–38 months) for PC of colorectal cancer and
130 months (95 % CI 98–162 months) for patients with
PMP.
Compared with the results of the randomized trial from
Verwaal et al.1,14 the proportion of complete cytoreduc-
tions has increased from 37 to 80 %. Major complication
and mortality rates were 34 and 3 % in this study, which is
comparable to the literature, but lower than in the ran-
domized trial. Even though patient selection has become
more cautious over the years, these results still suggest that
broader implementation of the treatment at least did not
have a negative consequence for the surgical outcome.
Survival rates for both PC from colorectal carcinoma
and PMP were comparable to literature. A number of CRS–
HIPEC studies have been published with survival numbers
for the different peritoneal surface malignancies. Most of
these studies are limited in numbers. The study with the
largest number that has recently been published is the
French multi-institutional study by Glehen et al.14 In this
study, 1,290 patients were included. Median follow-up was
45.3 months. Median overall survival was 30 months for
colorectal cancer and for PMP was not yet reached. Three-
and five-year survival was 41 and 26 % respectively for
colorectal carcinoma and 85 and 73 % for PMP. Twenty-
five institutions participated in the study with different
levels of expertise and with different treatment regimens.
In 86 % of the cases, HIPEC was performed either with
mitomycin C or oxaliplatin. EPIC instead of HIPEC was
performed in 14 % of the cases. The results of the present
study are roughly comparable to the results of the French
study. In both studies, a leading HIPEC centre might have
had a strong influence on the outcome. However, there is a
major difference in the wider use of the CRS and HIPEC
treatment. In the French study, the treatment protocols
differ between the hospitals, so the results reflect the mean
outcome of different CRS–HIPEC regimens, while in the
TABLE 2 Surgical outcome






















Cerebral vascular accident 1
No 928
Hospital stay 16 (0–166)
Days, median (range)
R1 no macroscopic residual disease, R2a/b macroscopic residual
disease
TABLE 3 Survival
PC of CRC PMP
n = 660 n = 300
PFS
Median (95 % CI) 15 (13–17) 53 (40–66)
OS
Median (95 % CI) 33 (28–38) 130 (98–162)
3-year 46 % 77 %
5-year 31 % 65 %
PFS progression-free survival in months, OS overall survival in
months, CI confidence interval
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Netherlands there is a unique situation; the use of a national
uniform treatment protocol.
Because HIPEC is only performed in specialised cen-
tres, there might be a certain patient selection. Some
oncologists claim that patients that choose to undergo a
HIPEC are generally younger, healthier, wealthier, and
more sensitive to chemotherapy. These patients might have
limited disease compared to patients who undergo che-
motherapy.22 However, there is no evidence on this subject
to confirm this clinical opinion. In this study, patients were
treated in one of the six hospitals that perform CRS–HI-
PEC in the Netherlands. The centres that participated are
different centres: academic, nonacademic, large periphery
hospitals, and a specialized cancer centre. So, not only
patients that are referred to tertiary referral hospitals are
included in this study, but also patients that present with
peritoneal malignancies in other hospitals. Inevitably, there
is a certain patient selection for CRS–HIPEC. The treat-
ment includes abdominal surgery, which has certain risks.
Patients in a nonoptimal physical and mental condition
with a large extent of disease do not benefit of the treat-
ment. Still, many patients, older and younger, are in a good
enough condition to undergo the treatment. Whether
patients in HIPEC studies are more sensitive to chemo-
therapy remains to be discussed. It has been studied that
administration of (neo) adjuvant chemotherapy is regularly
a prognostic factor for survival after CRS-HIPEC, though
the best timing and regimen are still unknown.14,23,24 The
purpose for this study was to investigate whether the
widespread availability of the CRS–HIPEC procedure to
more hospitals would endanger the outcome, but this we
could not confirm. Mentioned should be that patients in a
poor health status and having bowel obstructions are not
likely to be eligible for CRS–HIPEC, neither for systemic
chemotherapy.
Furthermore, critics state that modern day chemotherapy
has better results on metastatic colorectal cancer than the
5-fluorouracil based chemotherapy referred to in most
available publications.22 Yet, no studies have been pub-
lished that compare newest chemotherapy regimens with
CRS–HIPEC. Peritoneal metastases are not always ana-
lysed separately in large metastatic colorectal cancer
chemotherapy trials because of the difficulty in monitoring
the peritoneal lesions. CT scans and PET scans do not pick
up small peritoneal lesions easily, so response measure-
ment is problematic. Analysis of large combination
chemotherapy trials revealed that peritoneal carcinomatosis
among patients with metastatic colorectal cancer is asso-
ciated with a 30 % reduction in overall survival (10.7 vs.
17.6 months). These numbers are not fully comparable to
CRS–HIPEC studies, as the patients in this study regularly
have more metastatic sites, such as liver or lung metasta-
ses.8 In recent years, chemotherapy development has
progressed. There are indications that targeted therapies
can be useful to treat peritoneal metastasis from colorectal
cancer.9 In the CAIRO2 study, median survival for con-
ventional therapy, capecitabine with oxaliplatin and
bevacizumab, was 15.2 and 13.9 months for patients for
which cetuximab was added to the regimen. In future
studies, it would be interesting to investigate the benefit of
targeted therapies for patients with peritoneal metastases,
alone or in combination with CRS–HIPEC. Recently, the
COMBATAC trial has started to investigate the benefit of
adding targeted therapy to the CRS–HIPEC treatment.25
This study is limited by the multicentre design. More-
over, a disproportionate amount of patients was treated in
the Netherlands Cancer Institute (51 % of colorectal cancer
patients and 73 % of PMP patients) because of their longer
experience with the CRS–HIPEC procedure (Table 1). The

























FIG. 2 a Survival of patients
with PC of colorectal cancer
(n = 660) in Kaplan–Meier
survival curve. b Survival of
patients with PMP (n = 300) in
Kaplan–Meier survival curve.
OS overall survival, PFS
progression-free survival
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they all used the Dutch HIPEC protocol. Surgical outcome
appeared to be similar between the hospitals (unpublished
data).
This study shows that, following the randomized trial,
the Dutch protocol is a safe approach for widespread use of
the CRS–HIPEC treatment with tolerable morbidity and
convincing survival. It is important that more research is
performed to find better chemotherapy combined with
CRS–HIPEC for patients with peritoneal disease of colo-
rectal origin. Until then, CRS–HIPEC provides the best
chance of survival.
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